Status:
ACTIVE_NOT_RECRUITING
Long-Term Feedback Effect of FGM in Newly-Diagnosed T2D Patients
Lead Sponsor:
Campus Bio-Medico University
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial aims to evaluate the educational training of 12-weeks using flash glucose monitoring (FGM) FreeStyle Libre2 (FSL2; Abbott Diabetes Care Inc., Alameda, CA, USA) in newly- diagnosed ...
Detailed Description
Diabetes self-management represents the cornerstone of successful and cost-effective diabetes care, reducing the occurrence of complications, hospital admissions and readmission as well as estimated l...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes mellitus ( according to the ADA Guidelines ) within the past 12 months
- Must be taking only metformin as glucose lowering treatments,
- Older than 18 years,
- Body Mass Index equal or greater than 25 Kg/m\^2,
- Must be able to provide written informed consent .
Exclusion
- diagnosis of type 1 diabetes;
- glycated hemoglobin exceeding 8.5%
- alcohol or drug abuse/dependency
- antidiabetic therapy other than metformin;
- pregnancy (on-going or planned during the study);
- severe illness (physical or mental health);
- cognitive impairment;
- high dose steroids;
- hospitalized more than 2 times in past 12 months
- previous bariatric intervention or gastrectomy;
- pace maker use
- uncorrected vision impairment;
- already using a continuous glucose monitor or flash glucose monitor;
- any allergy to the component of the device.
Key Trial Info
Start Date :
September 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06098040
Start Date
September 22 2023
End Date
September 30 2025
Last Update
February 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario Campus Bio-Medico
Roma, Roma, Italy, 00100